Clinical Trial Update: Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for CRLX101 (NLG207) in advanced solid tumors (cancer), completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumor Cancer

Drugs mentioned

• CRLX101

Snippet

Sponsor: NewLink Genetics Corporation | Conditions: Cancer, Solid Tumor | Phase 1, Phase 2 | Status: COMPLETED